| 摘要 |
Disclosed are 2-(aryl)-4-oxo-quinazoline derivatives as represented by the general formula (II), wherein: X is N; R1 and R3 are each independently selected from alkoxy and hydrogen; R2 is selected from alkoxy, alkyl, and hydrogen; R6 and R8 are each independently selected from alkyl, alkoxy, chloride, and hydrogen; R5 is hydrogen; R7 is selected from amino, hydroxyl, alkoxy, and alkyl substituted with a heterocyclyl, or two adjacent substituents selected from R6, R7, and R8 are connected to form a heterocyclyl; R4 is hydrogen or is absent; each W is independently selected from C and N, wherein if W is N, then p is 0 or 1, and if W is C, then p is 1; with the proviso that if R2 is selected from alkoxy or hydrogen, then at least one of R1 and R3 is alkoxy; with the proviso that if R7 is selected from hydroxyl or alkoxy, then at least one of R6 and R8 are independently selected from alkyl, alkoxy, and chloride; with the proviso that if for W-(R7)p, W is N and p is 0, then at least one of R6 and R8 is chloride; and pharmaceutically acceptable salts and hydrates thereof. Representative compounds include 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one. Further disclosed is a pharmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier for treating or preventing a cardiovascular cholesterol or lipid related disorder in a mammal, and particularly where said disorder is atherosclerosis. |
